Previous 10 | Next 10 |
JERSEY CITY, N.J. , Dec. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share...
SCYNEXIS (NASDAQ: SCYX ) prices its public offering of ~38.9M common shares and warrants to purchase up to the same number of shares at $0.90 per share and accompanying warrant. More news on: SCYNEXIS, Inc., Healthcare stocks news, Stocks on the move, Read more ...
JERSEY CITY, N.J. , Dec. 10, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the pricing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share ...
SCYNEXIS (NASDAQ: SCYX ) is 17.8% lower postmarket after launching an offering of common stock and warrants. More news on: SCYNEXIS, Inc., Healthcare stocks news, Stocks on the move, Read more ...
JERSEY CITY, N.J. , Dec. 9, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants. In addition, SCYNEXIS expects to grant the underwriter a 30-day option to purchase up t...
JERSEY CITY, N.J. , Nov. 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today commended the Centers for Disease Control and Prevention (CDC) for the inclusion of...
SCYNEXIS (NASDAQ: SCYX ): Q3 GAAP EPS of -$0.15 beats by $0.07 . More news on: SCYNEXIS, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERSEY CITY, N.J. , Nov. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, 2019 , and prov...
Livongo Health (NASDAQ: LVGO ) +22% after Q3 results . More news on: Livongo Health, Inc., DexCom, Inc., InflaRx N.V., Stocks on the move, Read more ...
JERSEY CITY, N.J. , Oct. 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data from a post-hoc analysis of the Phase 2b DOVE study ...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...